An anti-glycation composition derived from natural products and its applications

Abstract

The present invention relates to the field of food technology, and particularly to a composition having anti-glycation activity, which composition comprises mangosteen extract and / or houttuynia cordata concentrated powder.

Description

Technical Field

[0001] The present invention relates to the technical field of anti-glycation compositions, and particularly to the anti-glycation effect of a composition containing mangosteen extract and / or houttuynia cordata concentrated powder. Background Art

[0002] The formation of advanced glycation end products (AGEs) is a complex biochemical process, mainly formed by a series of non-enzymatic catalytic reactions such as the initial reaction, rearrangement, oxidation, and polymerization between reducing sugars (such as glucose) and amino acids on proteins. This process is called the Maillard reaction. The formation of AGEs is closely related to the metabolism of sugar in the body. Regular intake of high-sugar foods will increase the level of sugar in the body, thus promoting the formation of AGEs. After the body is stimulated, free radicals generated by oxidative stress can accelerate the formation of AGEs. As people age, on the one hand, the Maillard reaction becomes more frequent, leading to the accumulation of more AGEs, and on the other hand, the body's metabolic rate slows down, and the clearance efficiency of AGEs decreases.

[0003] The formation process of AGEs plays an important role in skin aging and the development of many chronic diseases. AGEs can activate the body's immune response, resulting in an increase in the level of inflammation, which may have an adverse impact on health. The accumulation of AGEs is related to the development of various chronic diseases, such as diabetes, cardiovascular diseases, and neurodegenerative diseases. AGEs can form crosslinks with proteins, resulting in changes in protein function. For example, when AGEs crosslink with collagen or elastin, it will damage the structure and function of collagen and elastin, leading to a decrease in skin elasticity and the formation of wrinkles, thus accelerating the process of skin aging.

[0004] Anti-glycation strategies mainly refer to reducing the formation and accumulation of AGEs, as well as reducing their negative effects on the body. These strategies can be achieved through diet, lifestyle changes, increasing the intake of antioxidants, and drug treatment. Consuming foods rich in antioxidants, such as fresh fruits and vegetables, reducing blood sugar levels by reducing the intake of sugar and high-sugar foods, can all help reduce oxidative stress and the formation of AGEs. Moderate exercise helps improve insulin sensitivity and reduce blood sugar levels. Smoking and excessive alcohol consumption will both increase the formation of AGEs, while staying away from tobacco and alcohol can effectively reduce the production of AGEs. Some powerful antioxidants, such as vitamin C and E, can reduce the generation of free radicals, thus inhibiting the formation of AGEs. Aminoguanidine is a known drug with anti-glycation effects. It can inhibit the crosslinking of AGEs with proteins and reduce the damage of AGEs to the body. In addition, some natural herbal extracts have antioxidant and anti-inflammatory effects, showing anti-aging and anti-glycation effects, such as tea polyphenols, curcumin, resveratrol, etc.

[0005] Compared with chemically synthesized drugs, natural plant extracts are safer and have low toxicity or even no toxicity to the body. Compared with single components, plant extracts may contain multiple components, which also indicates the importance of evaluating the effects of plant extracts and compound preparations. So far, there have been few reports on the pharmacological activities of natural plant extracts in inhibiting the formation of AGEs. Summary of the Invention

[0006] In order to reduce the damage of AGEs to the body, the present invention provides a composition derived from natural products to counteract the formation of non-enzymatic AGEs, thereby reducing cell aging and health problems caused by AGEs.

[0007] By evaluating the anti-glycation effects of mangosteen extract, houttuynia cordata concentrated powder, and their compound mixture, the present invention proves that both substances have good effects in inhibiting the generation of AGEs, and proves that the anti-glycation effect of the compound mixture is higher than that of a single substance, which has important guiding significance for future anti-glycation research.

[0008] Mangosteen extract and houttuynia cordata concentrated powder can be purchased on the market and belong to raw materials in the conventional sense. Mangosteen extract can be purchased through commercial channels (Shin Yakuhin Co., Ltd., morusin glycoside ≥ 0.03%). Houttuynia cordata concentrated powder can be purchased through commercial channels (Ichimaru Pharcos Co., Ltd., quercetin ≥ 0.15%).

[0009] According to one aspect of the present invention, there is provided a composition derived from natural products, which comprises mangosteen extract and / or houttuynia cordata concentrated powder.

[0010] Preferably, the composition has anti-glycation activity.

[0011] Preferably, the composition has anti-glycation activity for inhibiting the formation of advanced glycation end products.

[0012] Preferably, the composition has anti-aging activity.

[0013] According to another aspect of the present invention, there is provided the use of a composition comprising mangosteen extract and / or houttuynia cordata concentrated powder in the preparation of oral beauty products.

[0014] Preferably, the oral beauty product is an oral liquid.

[0015] Mangosteen extract is rich in flavonoids, lignin, etc., and Houttuynia cordata concentrated powder contains flavonoid compounds. These antioxidant components can help neutralize free radicals, reduce oxidative stress, and combat inflammatory responses, thereby preventing cell damage and slowing down the aging process. The present invention further demonstrates that mangosteen extract and Houttuynia cordata concentrated powder have a high ability to inhibit the formation of AGEs, and after a certain combination of the two, they can synergistically play an anti-glycation role. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] The drawings described herein are used to provide a further understanding of the present invention and form a part of the present invention. The schematic embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation to the present invention. In the drawings:

[0017] Figure 1 Show the inhibition rate results of different substances on AGEs. DETAILED DESCRIPTION OF THE EMBODIMENTS

[0018] The following listed embodiments are to enable those skilled in the art to understand the present invention more clearly. It should be noted that the following embodiments do not limit the scope of protection required by the present invention and are only illustrative embodiments. The raw materials, reagents or devices mentioned in the following embodiments can be obtained from commercial channels or by known existing methods without special instructions.

[0019] In the context of the present invention disclosure, BSA refers to bovine serum albumin.

[0020] In the context of the present invention disclosure, MGO refers to methylglyoxal.

[0021] In the context of the present invention disclosure, weigh mangosteen extract and Houttuynia cordata concentrated powder in a certain proportion, add an appropriate amount of water to prepare a stock solution with a certain concentration, and dilute it appropriately before adding it to the reaction system to obtain a plant extract or compound mixture with high efficiency in inhibiting the formation of AGEs.

[0022] The following will explain the present invention in combination with the specific embodiments, and the scope of the present invention is not limited thereto. Example 1

[0023] Construct an in vitro AGEs formation system of BSA-MGO

[0024] In this invention, the final concentration of BSA was selected as 10 mg / ml, and the final concentrations of MGO were set as 0, 1 mM, 5 mM, 10 mM, 25 mM, 50 mM, 100 mM, and 150 mM respectively. In the constructed 3-ml reaction system, 100 μl of the reaction solution was taken each time and placed in a black 96-well microplate. The fluorescence value changes from 0 to 4 days were detected by a microplate reader under the conditions of an excitation wavelength of 370 nm and an emission wavelength of 440 nm. Table 1 shows the statistical data of the fluorescence value changes from 0 to 4 days in the in vitro AGEs generation system of BSA-MGO.

[0025] Table 1: Statistical data of the fluorescence value changes from 0 to 4 days in the in vitro AGEs generation system of BSA-MGO

[0026]

[0027] After 3 days, the multiple change of the fluorescence value began to slow down. Considering the time cost, 3 days was selected as the detection time point. At the same time, when the BSA concentration gradients were 10 mg / ml, 20 mg / ml, and 30 mg / ml respectively, the fluorescence values at 3 days in the in vitro AGEs generation system of BSA-MGO were detected. Table 2 shows the statistical data of the fluorescence value changes at 3 days in the in vitro AGEs generation system of BSA-MGO.

[0028] Table 2: Statistical data of the fluorescence value changes at 3 days in the in vitro AGEs generation system of BSA-MGO

[0029]

[0030] In summary, 10 mg / ml BSA and 25 mM MGO were selected as the subsequent modeling conditions, and the detection time point was the 3rd day after the reaction. Example 2

[0031] Anti-glycation effect evaluation experiment

[0032] Using the in vitro AGEs generation system of BSA-MGO constructed in Example 1, the abilities of mangosteen extract, houttuynia cordata concentrated powder, and the compound mixture to inhibit AGEs generation were evaluated, and 1 mM aminoguanidine was used as the positive control in this invention. Considering the differences in the initial fluorescence value readings when different types of plant extracts were added, the multiple change of the fluorescence value at the 3rd day relative to that at the 0th day was marked as F, and the inhibition rates of different plant extracts on AGEs were evaluated with different multiple changes. The multiple change of the model group was marked as F 模型 , and for the experimental groups corresponding to the addition of mangosteen extract and houttuynia cordata concentrated powder, the multiple changes of the reaction system at the 3rd day were marked as F 山竹提取物 , F 鱼腥草浓缩粉, the AGEs inhibition rate (%) is denoted as I. Taking the AGEs inhibition rate (%) of mangosteen extract as an example, I 山竹提取物 = 100×(F 模型 - F 山竹提取物 ) / F 模型 . The AGEs inhibition rate of Houttuynia cordata concentrated powder can be calculated in the same way.

[0033] In a 3 ml BSA-MGO in vitro AGEs generation system, add aminoguanidine with a final concentration of 1 mM, mangosteen extract with a concentration of 100 μg / ml, Houttuynia cordata concentrated powder with a concentration of 100 μg / ml, and a compound mixture with a final concentration of 100 μg / ml for both mangosteen extract and Houttuynia cordata concentrated powder. Then, use an enzyme-linked immunosorbent assay (ELISA) reader to detect the fluorescence intensity at the completion of the system addition (day 0) and 3 days after the reaction (day 3). Evaluate the ability of aminoguanidine, mangosteen extract, Houttuynia cordata concentrated powder, and the compound mixture to inhibit AGEs generation according to the AGEs inhibition rate formula.

[0034] Figure 1 It shows that the inhibition rate of aminoguanidine with a concentration of 1 mM on AGEs is 15.15%, the inhibition rate of mangosteen extract with a concentration of 100 μg / ml on AGEs is 14.46%, and the inhibition rate of Houttuynia cordata concentrated powder with a concentration of 100 μg / ml on AGEs is 5.99%. The inhibition rate of the compound mixture containing mangosteen extract and Houttuynia cordata concentrated powder on AGEs is as high as 25.64%, which is significantly higher than the inhibitory effect of mangosteen extract or Houttuynia cordata concentrated powder alone at the same concentration.

[0035] The combined effect of two drugs is evaluated using the King formula. The expression of the King formula: Q = E(a + b) / (Ea + Eb - Ea × Eb). Where Ea and Eb represent the effects of drugs a and b used alone, respectively; E(a + b) represents the effect of the combination of drug a and drug b. Evaluate whether the therapeutic effect of the two drugs after combination is better than that of single drug administration by interpreting the Q value. If Q is between 0.85 - 1.15, it is simple addition; if Q > 1.15, it is a synergistic effect; if Q < 0.85, it is an antagonistic effect.

[0036] Substitute the anti-glycation related data of mangosteen extract and Houttuynia cordata concentrated powder into the King formula, and the Q value of the inhibition rate of the compound mixture containing mangosteen extract and Houttuynia cordata concentrated powder on AGEs is 25.116 / (14.462 + 5.9914 - 14.462 * 5.9914) = 1.282284056, indicating that the compound mixture provided in Example 2 has a synergistic effect and can significantly increase the AGEs inhibition rate, thus achieving the effect of synergistic anti-glycation. It should be noted that when the final concentration ratio of mangosteen extract to Houttuynia cordata concentrated powder in the compound mixture is between 1:0.01 - 100, the above-mentioned synergistic anti-glycation effect is also observed.

[0037] In summary, the compound mixture in the embodiments of the present invention can significantly increase the AGEs inhibition rate, thereby achieving the effect of synergistic anti-glycation and delaying aging.

[0038] The above are only the preferred embodiments of the present invention and are not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and changes. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included within the protection scope of the present invention.

Claims

1. A composition derived from a natural product, characterized in that The active ingredients of the composition are mangosteen extract and houttuynia cordata concentrated powder, the content of moringin in the mangosteen extract is ≥0.03%, and the content of quercetin in the houttuynia cordata concentrated powder is above 0.15%; the final concentrations of the mangosteen extract and the houttuynia cordata concentrated powder are both 100 μg / ml.

2. Use of the composition according to claim 1 in the preparation of an anti-glycation product having the function of inhibiting the formation of advanced glycation end products.

Images